Which antidepressants are safe to use with hydroxychloroquine?

Safe Antidepressants to Use with Hydroxychloroquine

The safest antidepressants to combine with hydroxychloroquine are sertraline, venlafaxine, mirtazapine, and mianserin, as they cause minimal QT prolongation and negligible CYP2D6 inhibition, while citalopram and escitalopram are contraindicated due to severe torsades de pointes risk. 1

Contraindicated Antidepressants

Avoid these antidepressants entirely when prescribing hydroxychloroquine:

• Citalopram and escitalopram are absolutely contraindicated due to severe additive QT prolongation and torsades de pointes risk 1
• Tricyclic antidepressants (including amitriptyline) cause sodium channel blockade, QRS prolongation, and life-threatening cardiotoxicity when combined with hydroxychloroquine 1
• Fluoxetine, paroxetine, and bupropion are potent CYP2D6 inhibitors that can increase hydroxychloroquine levels 4- to 6-fold, raising toxicity risk 2, 3

High-Risk Antidepressants Requiring Extreme Caution

Use only with intensive cardiac monitoring:

• Duloxetine is a moderate CYP2D6 inhibitor causing 2- to 3-fold increases in metoprolol levels (similar concern with hydroxychloroquine) and requires dose adjustments 2, 3
• All SSRIs carry QT prolongation risk when combined with hydroxychloroquine, though severity varies by agent 1

Safest Antidepressant Options

These antidepressants have the most favorable safety profile with hydroxychloroquine:

• Sertraline is a weak CYP2D6 inhibitor with minimal QT effects at standard doses 2, 3
• Venlafaxine causes negligible CYP2D6 inhibition and minimal cardiac effects 2, 3
• Mirtazapine has no significant CYP2D6 inhibition and low QT risk 2, 3
• Mianserin shows no CYP2D6 inhibition and is not expected to cause clinically relevant interactions 2

Mandatory Cardiac Monitoring Protocol

Before initiating any antidepressant with hydroxychloroquine:

• Obtain baseline 12-lead ECG to measure QTc interval; withhold hydroxychloroquine if QTc ≥500 ms 4, 5
• Optimize electrolytes: correct potassium to 4.5-5.0 mmol/L and magnesium to >2.0 mg/dL, as hypokalemia dramatically increases arrhythmia risk 1, 5
• Screen all concurrent medications for other QT-prolonging agents (ondansetron, domperidone, azithromycin, certain antibiotics, antihistamines) 1

During therapy:

• Re-measure QTc at 2 weeks after starting the combination, then monthly 5
• Discontinue hydroxychloroquine immediately if QTc exceeds 500 ms or if ventricular arrhythmias develop 4, 5
• Monitor electrolytes regularly throughout treatment, as deficiencies markedly increase arrhythmia risk 1, 5

High-Risk Patient Populations

These patients require intensified monitoring or alternative treatment strategies:

• Pre-existing cardiac disease, bradycardia, or history of sudden cardiac death require enhanced cardiac surveillance 5
• Age >65 years and female sex are major independent risk factors for hydroxychloroquine-induced arrhythmias 5
• Structural heart disease increases risk of fatal arrhythmias with this combination 1
• Congenital long-QT syndrome is an absolute contraindication to hydroxychloroquine 5
• Concurrent use of diuretics or corticosteroids causing electrolyte disturbances amplifies cardiac risk 1

Clinical Evidence and Nuances

A 2021 study of 135 lupus patients found that concurrent use of hydroxychloroquine and antidepressants did not further increase QTc intervals beyond hydroxychloroquine alone in most patients; however, 7 patients (4 on hydroxychloroquine alone, 3 on combination therapy) developed QTc >500 ms, and most had underlying cardiac conditions 6. This underscores that baseline cardiac risk assessment is more predictive than drug combination alone.

The pharmacokinetic concern centers on CYP2D6 inhibition: hydroxychloroquine is a weak CYP2D6 inhibitor, and potent CYP2D6-inhibiting antidepressants can theoretically increase hydroxychloroquine levels 1, 7, 8. However, the primary clinical danger is pharmacodynamic—additive QT prolongation—not pharmacokinetic interaction 1.

Common Pitfalls to Avoid

• Do not assume all SSRIs are equivalent: citalopram/escitalopram carry contraindication while sertraline is safer 1
• Do not overlook over-the-counter medications that prolong QT (antihistamines, certain supplements) 1
• Do not conflate lack of pharmacokinetic interaction with absence of cardiac risk: even without drug-level changes, QT monitoring remains mandatory 5
• Do not withhold ECG monitoring based on the antidepressant chosen; hydroxychloroquine's intrinsic cardiac effects require surveillance regardless 5, 6

Additional Monitoring for Long-Term Therapy

For patients on chronic hydroxychloroquine (>5 years):

• Ophthalmologic screening every 6-12 months for irreversible retinopathy, the primary dose-limiting toxicity 9, 4
• Yearly ECG to monitor for cardiomyopathy and conduction abnormalities with prolonged exposure 9, 4
• Maximum dose 5 mg/kg actual body weight daily to minimize retinopathy risk 4